MITTAL PATEL: Open Payments
NPI 1093229619 · BELLEVILLE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$187 in 9 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $121 · 2025 $187
Food & beverage: $187
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 3 | $79 |
| Grifols USA, LLC | 1 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $14 |
| GlaxoSmithKline, LLC. | 1 | $14 |
Products named: Rhapsido, Xembify, Sajazir, CUVITRU, DUPIXENT, NEFFY, NUCALA.
Industry payments across NJ — which companies pay providers there.
